Stock Events

Stock Events

Nextcure 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2025
Next
Next
-1.97
-1.45
-0.92
-0.4
Expected EPS
-1.877458
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2US0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is involved in gene editing for cancer therapies, a direct competitor in innovative cancer treatments.
Novartis
NVS
Mkt Cap279.67B
Novartis is a large pharmaceutical company with a broad oncology portfolio, competing in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong presence in oncology and cell therapy, making it a competitor in cancer treatment.
Merck
MRK
Mkt Cap277.02B
Merck & Co. is known for its cancer drug Keytruda, directly competing with Nextcure's cancer immunotherapies.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb, with its range of oncology products, competes in the cancer immunotherapy market.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on human therapeutics, including oncology, competing with Nextcure in cancer treatment.

About

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Show more...
CEO
Mr. Michael S. Richman MSBA
Employees
43
Country
United States
ISIN
US65343E2072

Listings

XNAS
US
NXTC
F
DE
2US0.F
STU
DE
2US0.STU
MU
DE
2US0.MU

0 Comments

Share your thoughts

FAQ

What is Nextcure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nextcure stocks are traded under the ticker 2US0.STU.
When is the next Nextcure earnings date?▼
Nextcure is going to release the next earnings report on July 30, 2026.
How many employees does Nextcure have?▼
As of May 06, 2026, the company has 43 employees.
In which sector is Nextcure located?▼
Nextcure operates in the Health & Wellness sector.
When did Nextcure complete a stock split?▼
Nextcure has not had any recent stock splits.
Where is Nextcure headquartered?▼
Nextcure is headquartered in Beltsville, United States.